FIG. 8.
Bortezomib increases survival of SCID mice inoculated with EBV-transformed B cells. Kaplan-Meier survival curves were plotted for SCID mice inoculated with 0.5 × 106 (A) or 1 × 106 (B) LCLa cells. Seven days after inoculation, mice were treated with bortezomib (triangles) or PBS (squares) for a total of 6 weeks. Bortezomib treatment was stopped at 6 weeks because of weight loss in the mice. (C) Tissue lysates from tumors of bortezomib-treated or control mice were used for immunoblotting with antibodies to EBV LMP1, BZLF-1 protein, or EA-D. Tissues were analyzed when mice were moribund, which was approximately 5 weeks after the last dose of bortezomib. (D) LCLa cells were treated with various concentrations of bortezomib for 24 h and immunoblotted with antibody to BZLF-1. P3HR-1 cells treated with phorbol myristate acetate and butyrate served as a positive control in panels C and D.